Jardiance (empagliflozin) is a brand-name drug that’s prescribed for type 2 diabetes and more. As with other drugs, Jardiance can cause side effects, such as vaginal yeast infections and urinary tract ...

SAN DIEGO — The significant kidney and cardiovascular benefits people with chronic kidney disease (CKD) show over 2 years of treatment with empagliflozin begin to subside within about a year after ...

In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease ...

Jardiance is a diabetes medication that manages blood glucose levels, it is also used as a weight loss treatment. The active drug, Empagliflozin, although not technically a weight loss medication, ...

THURSDAY, June 26, 2025 (HealthDay News) -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial ...

The FDA has approved new oral therapies for children with type 2 diabetes — empagliflozin and a combination of empagliflozin and metformin hydrochloride — for the first time in more than 20 years. The ...

Intranasal insulin increased mPACC-5, modulated fractional anisotropy and cerebral blood flow. HealthDay News — Intranasal insulin (INI) and empagliflozin are safe and have promising effects on ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function. (HealthDay News) — Empagliflozin has kidney protective effects and reduces ...